Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.47 |
| ▸ | ALB | P02768 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.47 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | POLG | P54098 | 2/20 | 0.37 |
| ▸ | NT5E | P21589 | 2/20 | 0.35 |
| ▸ | POLA1 | P09884 | 1/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26135468 | 1.00 | PDE3A (0.47) | PDE3ALMNACACNA1FALBMAPT | |
| SCHEMBL24695861 | 1.00 | PDE3A (0.47) | PDE3ALMNACACNA1FALBMAPT | |
| SCHEMBL32670593 | 1.00 | PDE3A (0.47) | PDE3ALMNACACNA1FALBMAPT | |
| SCHEMBL938877 | 1.00 | PDE3A (0.47) | PDE3ALMNACACNA1FALBMAPT | |
| SCHEMBL9548789 | 0.90 | PDE3A (0.48) | PDE3ALMNACACNA1FALBMAPT | |
| SCHEMBL9548796 | 0.90 | PDE3A (0.48) | PDE3ALMNACACNA1FALBMAPT | |
| SCHEMBL26267576 | 0.87 | PDE3A (0.46) | PDE3ALMNACACNA1FALBMAPT | |
| SCHEMBL31653097 | 0.87 | PDE3A (0.46) | PDE3ALMNACACNA1FALBMAPT | |
| SCHEMBL20879387 | 0.85 | LMNA (0.52) | PDE3ALMNACACNA1FALBMAPT | |
| SCHEMBL18877436 | 0.82 | PDE3A (0.49) | PDE3ALMNACACNA1FALBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020022722-A1 | 4'-C-ethynyl pyrimidine nucleoside compounds | OHRUI HIROSHI (JP) | 2002-02-21 | — | — | US | claimed |
| US-6291670-B1 | VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-09-18 | — | — | US | claimed |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| US-12187758-B2 | Compounds and methods for treating disease | ROME THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240285664-A1 | LINE-1 INHIBITORS AS COGNITIVE ENHANCERS | TRANSPOSON THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| WO-2024103016-A1 | 4'-HALOMETHYL-CYTIDINE PHOSPHORAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ROME THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4346835-A1 | LINE-1 INHIBITORS AS COGNITIVE ENHANCERS | Transposon Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117813096-A | LINE-1 inhibitors as cognitive enhancer | 转位治疗股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230414616-A1 | LINE-1 INHIBITORS TO TREAT DISEASE | TRANSPOSON THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20070042988-A1 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC | 2007-02-22 | — | — | US | disclosed |
| WO-2007020193-A2 | ANTIVIRAL PHOSPHORAMIDATES OF 4 ' -SUBSTITUTED PRONUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006021341-A1 | ANTIVIRAL 4’-AZIDO-NUCLEOSIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-02 | — | — | WO | disclosed |
| US-20060040890-A1 | 4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one; hepatitis C virus. | ROCHE PALO ALTO LLC | 2006-02-23 | — | — | US | disclosed |
| EP-1177201-B1 | 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES | YAMASA CORP (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-6403568-B1 | FOR THERAPY OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) | YAMASA CORPORATION (JP) | 2002-06-11 | — | — | US | disclosed |
| US-20020022722-A1 | 4'-C-ethynyl pyrimidine nucleoside compounds | OHRUI HIROSHI (JP) | 2002-02-21 | — | — | US | disclosed |
| US-6333315-B1 | FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-12-25 | — | — | US | disclosed |
| US-6291670-B1 | VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042988-A1 | Antiviral phosphoramidates | RPP30, RNASE1, ADORA2B | PDE3A 794/4885LMNA 3990/4885CACNA1F 4773/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | PDE3A 4016/4885LMNA 2032/4885CACNA1F 1035/4885 |
| US-20020022722-A1 | 4'-C-ethynyl pyrimidine nucleoside compounds | PNP, TYMP, NUDT1 | PDE3A 648/4885LMNA 3211/4885CACNA1F 4076/4885 |
| US-20060040890-A1 | 4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one; hepatitis C virus. | HAVCR2, HCCS, CYP2S1 | PDE3A 2084/4885LMNA 4413/4885CACNA1F 4747/4885 |
| US-20230414616-A1 | LINE-1 INHIBITORS TO TREAT DISEASE | MAPT, LMNB1, PSEN1 | PDE3A 2724/4885LMNA 254/4885CACNA1F 1436/4885 |
| US-20240285664-A1 | LINE-1 INHIBITORS AS COGNITIVE ENHANCERS | PSEN1, PSEN2, MAPT | PDE3A 3018/4885LMNA 2208/4885CACNA1F 2137/4885 |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | PDE3A 4016/4885LMNA 2032/4885CACNA1F 1035/4885 |
| US-12187758-B2 | Compounds and methods for treating disease | EHMT1, POLRMT, RNASE1 | PDE3A 4016/4885LMNA 2032/4885CACNA1F 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.